Raia Drogasil SA Stock Sao Paulo
Stocks
DROG3
BRDROGACNOR1
Drug Retailers
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - BRL | - |
|
| 05-21 | Brazil's GPA sells stake in Stix for 23 million reais, ends joint venture | RE |
| 05-07 | Raia Drogasil S.A., Q1 2026 Earnings Call, May 06, 2026 |
| Market Cap | 32.68B 6.42B 5.63B 5.2B 4.78B 9.03B 619B 9.17B 62.19B 24.38B 303B 24.11B 23.58B 1,044B | P/E 2026 * |
21.9x | P/E 2027 * | 16.2x |
|---|---|---|---|---|---|
| Enterprise Value | 40.75B 8B 7.02B 6.49B 5.96B 11.25B 772B 11.43B 77.55B 30.4B 378B 30.06B 29.4B 1,301B | EV / Sales 2026 * |
0.89x | EV / Sales 2027 * | 0.79x |
| Free-Float |
73.24% | Yield 2026 * |
1.94% | Yield 2027 * | 2.48% |
Last Transcript: Raia Drogasil SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/01/2025 | |
| Director of Finance/CFO | 63 | 29/04/2013 | |
| Chief Operating Officer | 50 | 01/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 50 | 01/01/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.17% | +5.20% | +2.05% | +16.66% | 1.26B | |
| +1.20% | +2.13% | +10.31% | +24.82% | 482M | |
| -0.11% | -0.95% | -8.78% | +29.68% | 65.34M | |
| Average | +0.73% | +1.70% | +1.19% | +23.72% | 602.32M | |
| Weighted average by Cap. | +1.08% | +3.42% | +3.86% | +19.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 45.69B 8.98B 7.87B 7.27B 6.69B 12.62B 866B 12.82B 86.96B 34.09B 424B 33.71B 32.97B 1,459B | 52.75B 10.36B 9.08B 8.4B 7.72B 14.57B 999B 14.8B 100B 39.36B 489B 38.92B 38.07B 1,685B |
| Net income | 1.54B 303M 266M 246M 226M 426M 29.25B 433M 2.94B 1.15B 14.31B 1.14B 1.11B 49.31B | 2.07B 406M 356M 329M 303M 571M 39.17B 580M 3.94B 1.54B 19.17B 1.53B 1.49B 66.03B |
| Net Debt | 8.07B 1.58B 1.39B 1.28B 1.18B 2.23B 153B 2.26B 15.35B 6.02B 74.77B 5.95B 5.82B 258B | 8.89B 1.75B 1.53B 1.41B 1.3B 2.45B 168B 2.49B 16.91B 6.63B 82.37B 6.56B 6.41B 284B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RADL3 Stock
- DROG3 Stock
Select your edition
All financial news and data tailored to specific country editions
